Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.
Penile cancer statistics
New cases of penile cancer, 2014, UK
Deaths from penile cancer, 2014, UK
Survive penile cancer for 10 or more years, 2009-2013, England
Preventable cases of penile cancer, UK
- There were around 630 new cases of penile cancer in the UK in 2014, that’s around 2 cases diagnosed every day.
- Penile cancer accounts for less than 1% of all new cases in the UK (2014).
- In males, there were around 630 cases of penile cancer diagnosed in the UK in 2014.
- More than 4 in 10 (43%) penile cancer cases in the UK each year are diagnosed in males aged 70 and over (2012-2014).
- Incidence rates for penile cancer in the UK are highest in males aged 90+ (2012-2014).
- Since the early 1990s, penile cancer incidence rates in males have increased by a quarter (25%) in the UK.
- Over the last decade, penile cancer incidence rates in males have increased by almost a quarter (23%) in the UK.
- Most penis cancers occur in the glans penis.
- 1 in 585 men will be diagnosed with penile cancer during their lifetime.
- Penile cancer in England is more common in males living in the most deprived areas.
- There were around 130 penile cancer deaths in the UK in 2014, that’s more than 2 deaths every week.
- Penile cancer accounts for less than 1% of all cancer deaths in males in the UK (2014).
- In males in the UK, there were around 130 penile cancer deaths in 2014.
- Almost half (47%) of penile cancer deaths in the UK each year are in males aged 75 and over (2012-2014).
- Mortality rates for penile cancer in the UK are highest in males aged 90+ (2012-2014).
- Since the early 1970s, penile cancer mortality rates in males have decreased by a third (33%) in the UK.
- Over the last decade penile cancer mortality rates in males have remained stable in the UK.
- Penile cancer deaths in England are more common in males living in the most deprived areas.
- More than two-thirds (68%) of men diagnosed with penile cancer in England survive their disease for ten years or more (2009-2013).
- Around three-quarters (74%) of men diagnosed with penile cancer in England survive their disease for five years or more (2009-2013).
- Around 9 in 10 (89%) men diagnosed with penile cancer in England survive their disease for one year or more (2009-2013).
- Penile cancer survival in England is highest for men diagnosed aged under 50 years old (2009-2013).
- More than 8 in 10 men in England diagnosed with penile cancer aged 15-49 survive their disease for five years or more, compared with around two-thirds of men diagnosed aged 70-89 (2009-2013).
- Five-year relative survival for penile cancer in men is similar to the European average in England, Wales, Scotland and Northern Ireland.
- A person’s risk of developing cancer depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
- 40% of penile cancer cases each year in the UK are linked to major lifestyle and other risk factors.
- Human papillomavirus (HPV) infection is the main potentially avoidable risk factor for penile cancer, linked to an estimated 40% of penile cancer cases in the UK. Some other factors may relate to penile cancer risk partly because they are related to HPV.
- ‘Two-week wait’ standards are met by all countries, ‘31-day wait’ is met by all but Northern Ireland, and ‘62-day wait’ is not met by any country for upper gastrointestinal cancers.
- Almost 9 in 10 patients had a ‘very good’ or ‘excellent’ patient experience.
- Around three quarters of patients are given the name of their Clinical Nurse Specialist.
The latest statistics available for penile cancer in the UK are; incidence 2014, mortality 2014 and survival 2009-2013. Risk factors data are in production.
The ICD code for penile cancer is ICD-10 C60.
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2010-2012 due to the small number of cases.
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Penile cancer is part of the group 'Urological cancer' for cancer waiting times data. Codes vary per country but broadly include: penis, prostate, testis, other and unspecified male genital organs, kidney, renal pelvis, ureter, bladder, other and unspecified urinary organs, secondary cancers of kidney, renal pelvis, bladder and other unspecified urinary organs.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.
You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.
When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or